Bio-Techne Stock Price, News & Analysis (NASDAQ:TECH)

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12-month price objectives for Bio-Techne's stock. Their TECH share price targets range from $65.00 to $120.00. On average, they predict the company's share price to reach $91.80 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.

Bio-Techne's stock was trading at $82.88 at the start of the year. Since then, TECH shares have decreased by 24.1% and is now trading at $62.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our TECH earnings forecast.

Bio-Techne Co. (NASDAQ:TECH) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.39 by $0.04. The biotechnology company had revenue of $276.94 million for the quarter, compared to analysts' expectations of $289.81 million. Bio-Techne had a trailing twelve-month return on equity of 14.89% and a net margin of 21.57%.

Bio-Techne declared a quarterly dividend on Tuesday, October 31st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.08 per share on Friday, November 24th. This represents a $0.32 annualized dividend and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, November 9th.
Read our dividend analysis for TECH.

Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.52%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 21.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 16.16% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include American Century Mid Cap Growth Impact (MID), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Putnam BioRevolution ETF (SYNB), Fidelity Disruptive Medicine ETF (FMED) and Harbor Health Care ETF (MEDI).

Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were payable to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).

Bio-Techne's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bamco Inc. NY (3.40%), Morgan Stanley (2.09%), Bank of New York Mellon Corp (1.57%), Mackenzie Financial Corp (1.47%), William Blair Investment Management LLC (1.46%) and Ameriprise Financial Inc. (1.37%). Insiders that own company stock include Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.